Le Lézard
Classified in: Science and technology
Subjects: PDT, PLW

Opsera Announces New Patents for AI-powered, Cloud-Native Unified DevOps Platform


New patents highlight technical sophistication and market differentiation for Opsera's Unified Insights solution and DevOps Toolchain Automation capabilities

SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Opsera, the Cloud-Native Unified DevOps Platform trusted by innovative enterprise IT organizations around the globe, today announced that two new patents have been issued for its Unified DevOps Platform, now totaling nine patents issued for the most advanced and scalable cloud-native DevOps Platform in the market today.

Learn more about the Opsera Unified DevOps Platform: https://www.opsera.io/ 

Enterprise customers can utilize Opsera's sophisticated, patented technology to tap into powerful Unified Insights that enable businesses to make smart decisions, faster and adhere to strict compliance requirements. The Opsera Unified DevOps Platform is also patented to give developers flexibility and freedom of tool choice through toolchain automation that integrates with any tool on the market.

Improve Developer Experience (DevEx) & Productivity

Opsera customers transform their DevOps and DevSecOps journeys, increase agility by 25x, boost security posture by 60-75%, increase productivity 75%, and reduce Total Cost of Ownership by 2 to 3x.

The United States Patent and Trademark Office (USPTO) has issued the following patents to Opsera:

These patents are in addition to previously granted patents including U.S. Patent No. 11,416,266 entitled, "DevOps toolchain automation" and U.S. Patent No. 11,609,905 entitled, "Persona Based Analytics."

"We are pleased to continue to add new patents to our industry-leading Unified DevOps Platform," said Kumar Chivukula, co-founder and CEO of Opsera. "With Opsera, we are bringing innovative, patented technology to enterprise teams to give them the choice and flexibility with their tools and automation, while accelerating DevOps maturity and maintaining the highest levels of quality and security that cannot be found with other platforms on the market. Opsera improves developer experience, helps enterprises accelerate their modernization journey and provides the most comprehensive insights into the software delivery lifecycle."

About Opsera
Opsera is an AI-powered Cloud-Native Unified DevOps Platform that transforms the software development process for innovative IT organizations. Opsera empowers DevOps teams to accelerate software development release velocity, reduces DevOps tool sprawl by 66%, and increases developer productivity by 75%. With integrations to more than 100 existing DevOps tools, Opsera provides end-to-end insights and actionable intelligence, and new automated DevOps troubleshooting and remediation suggestions powered by Hummingbird AI. Deliver software and innovate faster, safer, smarter.

Contact:
Olivia Heel
Catapult PR
[email protected]

SOURCE Opsera


These press releases may also interest you

at 09:05
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...

at 09:05
F5 announced that it has been singled out as a visionary in API security for its F5 Distributed Cloud Web App and API Protection (WAAP) in Enterprise Management Associates' Vendor Vision 2024 report. The report highlights "must see" security...

at 08:05
GE HealthCare today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR...

at 08:00
Gateway Fiber's high-speed 100% fiber internet is branching out to...

at 02:34
Elbit Systems Ltd.  ("Elbit Systems" or the "Company") announced today that it was awarded an initial contract of approximately $37 million to supply Iron Fist Active Protection Systems (APS) to General Dynamics Ordnance and Tactical Systems...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...



News published on and distributed by: